MDA SPACE REPORTS SECOND QUARTER 2026 RESULTS

MDA Space reported Q2 2026 revenue of $498.6M (+33.6% YoY) and adjusted EBITDA of $96.3M (+26.2% YoY) with an unchanged 19.3% margin. Guidance was updated/raised: FY2026 revenue narrowed to $1.8–$1.9B (+~13% YoY at the midpoint) and adjusted EBITDA to $330–$370M (+~8% YoY at the midpoint), with capex reaffirmed at $225–$275M. Liquidity remains strong with net cash of $152.8M and total liquidity of $1.1B, though operating and free cash flow were negative (OCF $(93.4)M; FCF $(150.2)M) due to working-capital fluctuations.

Analysis

This is a backlog-conversion story with enough operating momentum to justify a near-term multiple lift, but not enough cash conversion to call it self-funding yet. The key market mechanism is that revenue growth is being funded by working capital and capex, so headline EBITDA upside is real while free-cash-flow quality remains fragile; that tends to cap how far the stock can rerate before investors demand proof of monetization.

The second-order winner is the defense/sovereign-space value chain: program visibility and national-security procurement reduce cancellation risk, but they also concentrate exposure to a handful of lumpy contracts and execution milestones. That creates a beneficiary set around prime contractors and niche components/services, while traditional launch-adjacent or lower-value-added space names risk being left behind if capital shifts toward vertically integrated, cash-backed platforms.

Contrarianly, the market may be underestimating how much of the growth is being “bought” through higher capex, integration cost, and share-count dilution. If management can keep EBITDA margin in range while converting backlog without further stretching working capital, the stock can grind higher over 6-18 months; if not, the story reverts to a capital-intensive integrator deserving a lower multiple than a software-like growth asset. Falsifier: two straight quarters of weak operating cash flow or a guide cut below the current margin band.

Key Decisions for Investors

• Long MDA on post-print weakness over the next 1-3 months; the better entry is a pullback after the initial guidance-driven pop, with upside tied to backlog conversion rather than incremental bookings.
• Pair trade: long MDA / short ITA or XAR for 1-3 months if the market is bidding up all defense-beta equally; MDA has more idiosyncratic backlog visibility but also more cash-flow execution risk.
• If already long MDA, trim into strength and wait for the next operating cash flow print before adding; free-cash-flow negativity is the main reason the rerating can stall even if revenue keeps compounding.
• Set an alert on operating cash flow and capex trends for the next quarter; if working capital remains a drag and FCF does not improve, reduce exposure regardless of EBITDA guidance stability.